• Infliximab, adalimumab, golimumab, certolizumab, etanercept

• Refractory RA, PsA, AxSpA, JIA 
• Refractory Crohn’s disease/Crohn’s fistula
• UC not responding to optimal medical therapy (except etanercept)
• Sarcoidosis
• Psoriasis

• Rituximab, Obinutuzumab

• Ocrelizumab

• CD 20 (+) ve lymphoma/CLL/WMG
• Refractory RA/ITP/HUS/TTP 
• GPA, MPA, Takayasu’s arteritis
• Pemphigus vulgaris

• Multiple sclerosis

• Abciximab

• High risk coronary artery intervention (PCI)

• Belatacept

• Immunosuppression in organ transplantation

• Tocilizumab

• Sarilumab

• Severe COVID-19
• Refractory RA
• GCA, JIA, SSC-ILD

• RA

• Omalizumab

• Add on therapy in severe allergic asthma uncontrolled on high dose ICS-LABA/ABPA
• Nasal polyps 
• Chronic idiopathic urticaria/HES

• Mepolizumab

IL-5R inhibitor

• Benralizumab

• Add on therapy in severe eosinophilic asthma uncontrolled on high dose ICS-LABA

• Eculizumab

• PNH/HUS

• Belimumab

• Mild to moderate SLE non-responding/inadequately responding to standard therapy

• Ustekinumab

• PSA
• Psoriasis
• Moderate to severe CD & UC
• Maintaining remission in anti-TNF failure UC

• Denosumab SC

Sclerostin (anti-anabolic effects on bone formation)

• Romosozumab ***

• Osteoporosis

• Burosumab SC ***

1. Sorafenib

1. Lenvatinib ***

1. Regorafenib***  (SLR)

1. Sunitinib, Pazopanib

1. Primary HCC, AML with FLT3-ITD gene mutation
2. Primary HCC (alternative to sorafenib)

1. Primary HCC (second line therapy)

1. RCC

• Daratumab

• MM

1. Canakinumab

1. Anakinra

1. CAPS (cryopyrin-associated periodic syndromes), sJIA, AOSD, gout

1. RA, CAPS, AOSD, gout

1. Secukinumab, Ixekizumab

1. Broadalumab

1. PsA, axSpA, psoriasis 

1. Psoriasis

• Guselkumab

• PSA, psoriasis

• Abatacept

• RA, PsA, JIA

1. Apremilast

1. Crisaborole **

1. Psoriasis & PSA 

1. Psoriasis

1. Gefitinib, Erlotinib, Osimertinib

1. Cetuximab Panitumumab

1. Lung ca

1. Colorectal ca (metastatic)

• Transtuzumab, Pertuzumab

• HER-2 (+)ve breast ca/gastric ca